ReviewResearch and reports in urology2022
Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers.
Review in Research and reports in urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence of osteoporosis and low bone mass in men with prostate cancer: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Efficacy of androgen deprivation therapy (ADT) in combination with radiation therapy, compared to ADT alone in patients with high-risk prostate cancer: an updated systematic review and meta-analysis.Journal of medicine and life · 2026Pooled it
- Darolutamide Alone and in Combination With Goserelin in Androgen Receptor-Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Androgen receptor pathway inhibitor intensification in non-metastatic hormone-sensitive prostate cancer: current evidence and clinical implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Real-World Longitudinal Treatment Outcomes for Patients with Metastatic Castration-Sensitive Prostate Cancer in Japan.Advances in therapy · 2026Article
- The logarithmic phase as a therapeutic direction: evaluating pharmacological strategies against cancer progression.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Gold Nanoparticles in Prostate Cancer: Advances in Targeted Therapy, Diagnostics, and Precision Nanomedicine.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Article
- Comparative preclinical assessment of relugolix tablets and relugolix intravenous injection.Scientific reports · 2026Article
- Designing a molecularly imprinted polymer sensor for sensitive and selective detection of the prostate cancer drug Abiraterone acetate.Scientific reports · 2026Article
- Article
- Intermittent androgen deprivation therapy for biochemical recurrence or prostate-specific antigen (PSA) persistence after radical prostatectomy: efficacy and prognostic factors.Translational andrology and urology · 2026Article
- Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancer.Prostate cancer and prostatic diseases · 2026Article
- Article
- The interrelationship between prostate cancer and osteoporosis: new perspectives on shared molecular pathways and treatment strategies.International journal of surgery (London, England) · 2026Article
- Magnocurarine inhibits migration and invasion by suppressing mesenchymal marker expression and MAPK signaling in castration-resistant prostate cancer cells.Frontiers in pharmacology · 2026Article
- SSTDhunter: a curated gene database for investigating androgen producing potential in microbiota species.Frontiers in cellular and infection microbiology · 2026Article
- RAB40C regulates SNX9 stabilityCentral-European journal of immunology · 2026Article
- In Vitro Effects of Cabazitaxel and Menadione on Cell Growth, Metabolism, and Transcriptomic Profile of Human Prostate Cancer Cell Lines.Prostate cancer · 2026Article
- Metformin and Flutamide Combination Therapy's Efficacy and Safety in Prostate Cancer Cell Lines.Prostate cancer · 2026Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Androgen deprivation therapy (ADT) has been the main management strategy for prostate cancer for more than eight decades, nowadays achieved commonly by administration of luteinizing hormone-releasing hormone agonists. ADT markedly suppresses androgen hormones with the long-term risks of adverse events such as muscle weakness, impairment of glucose and lipid metabolism, impotence, osteoporosis, and secondary fractures. Extensive research has provided significantly better insight into the dynamics of ADT including identification of the benefits of sequential and combination therapies. This has led to the development of new pharmaceutical ADT modalities. This review provides a general overview of the evolution of ADT in the context of the new emerging pharmaceutical ADT modalities so that clinicians and medical providers have a better understanding of personalizing the available ADT options with their different risk-benefit profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.